XLO — Xilio Therapeutics Balance Sheet
0.000.00%
- $35.81m
- $1.83m
- 12
- 22
- 45
- 16
Annual balance sheet for Xilio Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 48.8 | 19.2 | 198 | 120 | 44.7 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 51.1 | 20.6 | 203 | 124 | 48.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 9.87 | 13.7 | 13.9 | 13.1 | 11.2 |
Other Long Term Assets | |||||
Total Assets | 62.7 | 36.3 | 218 | 139 | 60.9 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.21 | 22.2 | 12.8 | 21.1 | 16 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 24.2 | 41.6 | 32.6 | 33.5 | 24.1 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 38.5 | -5.29 | 185 | 106 | 36.8 |
Total Liabilities & Shareholders' Equity | 62.7 | 36.3 | 218 | 139 | 60.9 |
Total Common Shares Outstanding |